Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01071954 · ClinicalTrials.gov registry record · Phase 3
A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Patients With Immune (Idiopathic) Thrombocytopenia Purpura
A Phase 3 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 66
- Enrollment target
NCT01071954 is a Phase 3 study that has completed, run by Amgen. The registered enrollment target is 66 participants.
The verdict
NCT01071954, a Phase 3 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 66 participants
- Enrollment target
Study Summary
This is an extension study designed to assess the safety and durability of platelet count increases with romiplostim treatment of thrombocytopenic patients with immune (Idiopathic) thrombocytopenia purpura. This study is available to pediatric patients who have completed a previous romiplostim ITP study and meet the eligibility criteria of this study.
Interventions
- BIOLOGICAL Romiplostim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2009-12-30 |
| Est. Completion | 2017-01-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01071954
The ClinicalTrials.gov registry entry for NCT01071954 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Romiplostim is the first listed.
NCT01071954 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01071954 about?
NCT01071954 is a clinical study titled "A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Patients With Immune (Idiopathic) Thrombocytopenia Purpura". This is an extension study designed to assess the safety and durability of platelet count increases with romiplostim treatment of thrombocytopenic patients with immune (Idiopathic) thrombocytopenia purpura. This study is available to pediatric patients who have completed a previous romiplostim ITP s...
What is the current status of trial NCT01071954?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 66 participants. The study started on 2009-12-30. Estimated completion is 2017-01-12.
What interventions are being tested in trial NCT01071954?
The interventions under investigation include: Romiplostim (BIOLOGICAL).
Who is sponsoring clinical trial NCT01071954?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.